PARPis
4 abstracts
Abstract
Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting.Org: Cleveland Clinic Brunswick Urgent Care, Center for Immunotherapy and Precision Immuno-Oncology,
Abstract
Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,
Abstract
The role of Chemotherapy Response Score (CRS) in the decision making process for advanced high grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy.Org: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Catholic University of the Sacred Heart, Rome, Italy, Fondazione Policlinico Universitario A. Gemelli IRCCS, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Identification of novel actionable SNVs using targeted comprehensive genome profiling in patients with sarcoma.Org: OneCell Dx, Pune, Indiana University – Purdue University Indianapolis, Indx Technology, Cupertino, CA,